Ambrx Biopharma Inc. Comprehensive Income
Ambrx Biopharma Inc. reported Comprehensive Income of -$78.51 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2023-03-30
- Ambrx Biopharma Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$78.51M.
- Ambrx Biopharma Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$68.10M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|
| 2022-12-31 | -$78.51M 10-K · filed 2023-03-30 | |
| 2022-06-30 | -$51.71M 6-K · filed 2022-08-29 | |
| 2021-12-31 | -$68.10M 10-K · filed 2023-03-30 | |
| 2021-06-30 | -$29.03M 6-K · filed 2022-08-29 | |
| 2020-12-31 | -$16.39M 20-F · filed 2022-04-26 | |
| 2019-12-31 | -$20.10M 20-F · filed 2022-04-26 |